Indications and uses
temporarily relieves nasal congestion due to: ▪ a cold ▪ hay fever ▪ upper respiratory allergies ▪ helps clear nasal passages; shrinks swollen membranes ▪ temporarily restores freer breathing through the nose
temporarily relieves nasal congestion due to: ▪ a cold ▪ hay fever ▪ upper respiratory allergies ▪ helps clear nasal passages; shrinks swollen membranes ▪ temporarily restores freer breathing through the nose
adults and children 6 to under 12 years of age (with adult supervision): 2 or 3 sprays in each nostril not more often than every 10 to 12 hours. Do not exceed 2 doses in any 24 hour period children under 6 years of age : ask a doctor Squeeze and unscrew to remove the protective cap. Align rail grooves and prime pump by depressing it firmly several times (see illustration on side). Hold bottle with thumb at base an...
Drug Facts
oxymetazoline hydrochloride 0.05%
Nasal decongestant
symptoms persist
ask a health professional before use.
If swallowed, get medical help or contact a Poison Control Center (1-800-222-1222) right away.
Squeeze and unscrew to remove the protective cap. Align rail grooves and prime pump by depressing it firmly several times (see illustration on side). Hold bottle with thumb at base and nozzle between first and second fingers. With head upright, insert nozzle into nostril. Depress pump two or three times, all the way down, and sniff deeply.
benzalkonium chloride, edetate disodium, glycerin, polyethylene glycol, povidone, propylene glycol, sodium phosphate dibasic, sodium phosphate monobasic, water
1-800-344-7239
Nōstrilla®
Oxymetazoline HCl Nasal Solution
NASAL DECONGESTANT
1/2 FL. OZ (15 mL)
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 726062af-1135-4707-a1d7-57256991bbf9 | Product name | 2 | 20250226 |
| e67be450-f8e4-4bc1-88bd-1259d379f55f | Product name | 1 | 20210127 |
| c53f3286-4062-4cf5-8355-399519c639a6 | Product name | 1 | 20170424 |
| a993dfc5-f219-4460-bde6-30dd724d9ef0 | Product name | 1 | 20160818 |
| 19c71a3d-ed9c-166b-a7e5-38c250c35631 | Product name | 1 | 20140508 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 63736-730-01 | 2020-04-10 | C162847 | 48780-1 | 9d75b9d0-e6f2-f424-e053-dadaa90a57ce | Nostrilla |
| 63736-730-01 | 2020-04-10 | C162847 | 48780-1 | 9d75b9d0-e6f2-f424-e053-dadaa90a57ce | Nostrilla |
| 63736-730-02 | 2020-04-10 | C162847 | 48780-1 | 9d75b9d0-e6f2-f424-e053-dadaa90a57ce | Nostrilla |
| 63736-730-02 | 2020-04-10 | C162847 | 48780-1 | 9d75b9d0-e6f2-f424-e053-dadaa90a57ce | Nostrilla |
| 63736-730-01 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-e6f2-f424-e053-dadaa90a57ce | Nostrilla |
| 63736-730-01 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-e6f2-f424-e053-dadaa90a57ce | Nostrilla |
| 63736-730-02 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-e6f2-f424-e053-dadaa90a57ce | Nostrilla |
| 63736-730-02 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-e6f2-f424-e053-dadaa90a57ce | Nostrilla |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Oxymetazoline Hydrochloride | ACTIVE INGREDIENT | K89MJ0S5VY | 2 | |
| Oxymetazoline | ACTIVE MOIETY | 8VLN5B44ZY | 2 | |
| benzalkonium chloride | INACTIVE INGREDIENT | F5UM2KM3W7 | 2 | |
| glycine | INACTIVE INGREDIENT | TE7660XO1C | 2 | |
| hydrochloric acid | INACTIVE INGREDIENT | QTT17582CB | 2 | |
| sorbitol | INACTIVE INGREDIENT | 506T60A25R | 2 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 63736-730 | 63736-730-01, 63736-730-02 |
Every source-derived ingredient row is available through these pages.
| Version | Effective date | Source | Hydrated |
|---|---|---|---|
| 7 | 2024-10-25 | full-release | 2026-06-01 00:36:42 |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| glycine | GLYCINE | TE7660XO1C | INJECTION, POWDER, FOR SOLUTION / INTRADERMAL | 0.5 mg | ||
| sorbitol | SORBITOL | 506T60A25R | SOLUTION / NASAL | 25 mg/1ml | ||
| glycine | GLYCINE | TE7660XO1C | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 40 mg | ||
| glycine | GLYCINE | TE7660XO1C | TABLET / ORAL | 163.31 mg | ||
| glycine | GLYCINE | TE7660XO1C | INJECTION / INTRAVENOUS | 200 mg | ||
| benzalkonium chloride | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SPRAY, METERED / NASAL | 1 mg | ||
| glycine | GLYCINE | TE7660XO1C | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 3.76 mg | ||
| glycine | GLYCINE | TE7660XO1C | CAPSULE, DELAYED RELEASE / ORAL | 50 mg | ||
| glycine | GLYCINE | TE7660XO1C | POWDER, FOR SUSPENSION / ORAL | 400 mg | ||
| glycine | GLYCINE | TE7660XO1C | INJECTION, POWDER, FOR SOLUTION / INTRADERMAL | 0.5 mg | ||
| sorbitol | SORBITOL | 506T60A25R | SOLUTION / NASAL | 25 mg/1ml | ||
| glycine | GLYCINE | TE7660XO1C | CAPSULE / ORAL | 62 mg | ||
| glycine | GLYCINE | TE7660XO1C | TABLET, CHEWABLE / ORAL | 267 mg | ||
| glycine | GLYCINE | TE7660XO1C | POWDER, FOR SOLUTION / ORAL | 0.09 mg | ||
| glycine | GLYCINE | TE7660XO1C | INJECTION, SOLUTION / INTRAVENOUS | 0.42 %w/v | ||
| glycine | GLYCINE | TE7660XO1C | CAPSULE, DELAYED RELEASE / ORAL | 50 mg | ||
| glycine | GLYCINE | TE7660XO1C | POWDER, FOR SOLUTION / ORAL | 0.09 mg | ||
| glycine | GLYCINE | TE7660XO1C | TABLET, CHEWABLE / ORAL | 267 mg | ||
| glycine | GLYCINE | TE7660XO1C | TABLET, ORALLY DISINTEGRATING / ORAL | 60 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SPRAY, METERED / NASAL | ADJ PH | ||
| sorbitol | SORBITOL | 506T60A25R | SOLUTION / NASAL | 25 mg/1ml | ||
| glycine | GLYCINE | TE7660XO1C | TABLET / ORAL | 163.31 mg | ||
| glycine | GLYCINE | TE7660XO1C | SOLUTION / ORAL | 50 mg | ||
| glycine | GLYCINE | TE7660XO1C | INJECTABLE, LIPOSOMAL / INTRAVENOUS | 0.38 %w/v | ||
| glycine | GLYCINE | TE7660XO1C | TABLET / ORAL | 163.31 mg | ||
| benzalkonium chloride | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SPRAY, METERED / NASAL | 1 mg | ||
| glycine | GLYCINE | TE7660XO1C | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 40 mg | ||
| glycine | GLYCINE | TE7660XO1C | PASTE, DENTIFRICE / DENTAL | 0.34 %w/w | ||
| glycine | GLYCINE | TE7660XO1C | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 0.5 mg | ||
| glycine | GLYCINE | TE7660XO1C | CAPSULE, DELAYED RELEASE / ORAL | 50 mg | ||
| glycine | GLYCINE | TE7660XO1C | POWDER / RESPIRATORY (INHALATION) | 2 mg | ||
| glycine | GLYCINE | TE7660XO1C | INJECTION, POWDER, FOR SOLUTION / INTRADERMAL | 0.5 mg | ||
| benzalkonium chloride | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SPRAY, METERED / NASAL | 1 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SPRAY, METERED / NASAL | ADJ PH | ||
| glycine | GLYCINE | TE7660XO1C | CAPSULE / ORAL | 62 mg | ||
| glycine | GLYCINE | TE7660XO1C | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 10 mg | ||
| glycine | GLYCINE | TE7660XO1C | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 0.5 mg | ||
| glycine | GLYCINE | TE7660XO1C | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 10 mg | ||
| glycine | GLYCINE | TE7660XO1C | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 10 mg | ||
| glycine | GLYCINE | TE7660XO1C | POWDER, FOR SUSPENSION / ORAL | 400 mg | ||
| glycine | GLYCINE | TE7660XO1C | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 200 mg | ||
| glycine | GLYCINE | TE7660XO1C | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 0.5 mg | ||
| glycine | GLYCINE | TE7660XO1C | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 3.76 mg | ||
| sorbitol | SORBITOL | 506T60A25R | SPRAY / NASAL | 49 mg | ||
| glycine | GLYCINE | TE7660XO1C | INJECTION, SOLUTION / INTRAVENOUS | 0.42 %w/v | ||
| glycine | GLYCINE | TE7660XO1C | TABLET, ORALLY DISINTEGRATING / ORAL | 60 mg | ||
| glycine | GLYCINE | TE7660XO1C | POWDER / RESPIRATORY (INHALATION) | 2 mg | ||
| glycine | GLYCINE | TE7660XO1C | INJECTION / INTRAMUSCULAR | 68 mg | ||
| glycine | GLYCINE | TE7660XO1C | PASTE, DENTIFRICE / DENTAL | 0.34 %w/w | ||
| glycine | GLYCINE | TE7660XO1C | INJECTION, SOLUTION / INTRAVENOUS | 0.42 %w/v | ||
| glycine | GLYCINE | TE7660XO1C | CAPSULE / ORAL | 62 mg | ||
| glycine | GLYCINE | TE7660XO1C | SOLUTION / ORAL | 50 mg | ||
| glycine | GLYCINE | TE7660XO1C | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 3.76 mg | ||
| glycine | GLYCINE | TE7660XO1C | INJECTION / INTRAVENOUS | 200 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SPRAY, METERED / NASAL | ADJ PH | ||
| sorbitol | SORBITOL | 506T60A25R | SPRAY / NASAL | 49 mg | ||
| glycine | GLYCINE | TE7660XO1C | POWDER / RESPIRATORY (INHALATION) | 2 mg | ||
| glycine | GLYCINE | TE7660XO1C | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 200 mg | ||
| glycine | GLYCINE | TE7660XO1C | POWDER, FOR SOLUTION / ORAL | 0.09 mg | ||
| glycine | GLYCINE | TE7660XO1C | POWDER, FOR SUSPENSION / ORAL | 400 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Nostrilla | OXYMETAZOLINE HYDROCHLORIDE | Insight Pharmaceuticals LLC | 86217847-8e2b-48cc-b289-4987fd3aa7c3 | 2026-09-04 | Warnings | 63736-730-01 63736-730-02 63736-730 63736073002 63736073001 5ab00067-efa6-fc48-e063-6294a90a6499 86217847-8e2b-48cc-b289-4987fd3aa7c3 |
Adverse event summaries are temporarily unavailable. Other product information remains available.